Literature DB >> 17280785

Identification of early disease progression in an ALS rat model.

Jason R Thonhoff1, Paivi M Jordan, Joseph R Karam, Brandon L Bassett, Ping Wu.   

Abstract

Transgenic rat models of amyotrophic lateral sclerosis (ALS) have recently been developed. Most assays of ALS-symptoms in these models monitor disease onset accurately, but do not identify individuals that will develop these symptoms before the motor deficits become apparent. Peak bodyweight has recently been shown to indicate affected individuals before motor deficits become apparent. However, it must be determined retrospectively due to weight fluctuation. Here, we report that exploratory activities detected by a photobeam activity system (PAS) and wire mesh ascending test can be used to detect slight motor deficits in the early phase of ALS. Thus, these tests may be used in addition to peak bodyweight to monitor early disease progression and to assay efficacy of new therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17280785      PMCID: PMC1876693          DOI: 10.1016/j.neulet.2007.01.028

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  18 in total

1.  Rats expressing human cytosolic copper-zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis: associated mutations develop motor neuron disease.

Authors:  M Nagai; M Aoki; I Miyoshi; M Kato; P Pasinelli; N Kasai; R H Brown; Y Itoyama
Journal:  J Neurosci       Date:  2001-12-01       Impact factor: 6.167

2.  Colivelin prolongs survival of an ALS model mouse.

Authors:  Tomohiro Chiba; Marina Yamada; Jumpei Sasabe; Kenzo Terashita; Sadakazu Aiso; Masaaki Matsuoka; Ikuo Nishimoto
Journal:  Biochem Biophys Res Commun       Date:  2006-03-10       Impact factor: 3.575

3.  Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice.

Authors:  Shan Zhu; Irina G Stavrovskaya; Martin Drozda; Betty Y S Kim; Victor Ona; Mingwei Li; Satinder Sarang; Allen S Liu; Dean M Hartley; Du Chu Wu; Steven Gullans; Robert J Ferrante; Serge Przedborski; Bruce S Kristal; Robert M Friedlander
Journal:  Nature       Date:  2002-05-02       Impact factor: 49.962

4.  Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS).

Authors:  David S Howland; Jian Liu; Yijin She; Beth Goad; Nicholas J Maragakis; Benjamin Kim; Jamie Erickson; John Kulik; Lisa DeVito; George Psaltis; Louis J DeGennaro; Don W Cleveland; Jeffrey D Rothstein
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-29       Impact factor: 11.205

5.  N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis.

Authors:  O A Andreassen; A Dedeoglu; P Klivenyi; M F Beal; A I Bush
Journal:  Neuroreport       Date:  2000-08-03       Impact factor: 1.837

6.  Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis.

Authors:  Li-Jun Wang; Yan-Yan Lu; Shin-ichi Muramatsu; Kunihiko Ikeguchi; Ken-ichi Fujimoto; Takashi Okada; Hiroaki Mizukami; Takashi Matsushita; Yutaka Hanazono; Akihiro Kume; Toshiharu Nagatsu; Keiya Ozawa; Imaharu Nakano
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

7.  Behavioural and anatomical effects of systemically administered leukemia inhibitory factor in the SOD1(G93A G1H) mouse model of familial amyotrophic lateral sclerosis.

Authors:  Michael F Azari; Elizabeth C Lopes; Chantelle Stubna; Bradley J Turner; Dawei Zang; Nicos A Nicola; John B Kurek; Surindar S Cheema
Journal:  Brain Res       Date:  2003-08-22       Impact factor: 3.252

8.  Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice.

Authors:  Hong Guo; Liching Lai; Matthew E R Butchbach; Michael P Stockinger; Xiu Shan; Georgia A Bishop; Chien-liang Glenn Lin
Journal:  Hum Mol Genet       Date:  2003-08-05       Impact factor: 6.150

Review 9.  Unraveling the mechanisms involved in motor neuron degeneration in ALS.

Authors:  Lucie I Bruijn; Timothy M Miller; Don W Cleveland
Journal:  Annu Rev Neurosci       Date:  2004       Impact factor: 12.449

10.  Minocycline delays disease onset and mortality in a transgenic model of ALS.

Authors:  Ludo Van Den Bosch; Petra Tilkin; Griet Lemmens; Wim Robberecht
Journal:  Neuroreport       Date:  2002-06-12       Impact factor: 1.837

View more
  5 in total

1.  Lysophosphatidic acid and amitriptyline signal through LPA1R to reduce P-glycoprotein transport at the blood-brain barrier.

Authors:  David B Banks; Gary Ny Chan; Rebecca A Evans; David S Miller; Ronald E Cannon
Journal:  J Cereb Blood Flow Metab       Date:  2017-04-27       Impact factor: 6.200

2.  Selective induction of P-glycoprotein at the CNS barriers during symptomatic stage of an ALS animal model.

Authors:  Gary N Y Chan; Rebecca A Evans; David B Banks; Emily V Mesev; David S Miller; Ronald E Cannon
Journal:  Neurosci Lett       Date:  2016-12-21       Impact factor: 3.046

3.  Acute Colon Inflammation Triggers Primary Motor Cortex Glial Activation, Neuroinflammation, Neuronal Hyperexcitability, and Motor Coordination Deficits.

Authors:  Livia Carrascal; María D Vázquez-Carretero; Pablo García-Miranda; Ángela Fontán-Lozano; María L Calonge; Anunciación A Ilundáin; Carmen Castro; Pedro Nunez-Abades; María J Peral
Journal:  Int J Mol Sci       Date:  2022-05-11       Impact factor: 6.208

4.  Mutant SOD1 microglia-generated nitroxidative stress promotes toxicity to human fetal neural stem cell-derived motor neurons through direct damage and noxious interactions with astrocytes.

Authors:  Jason R Thonhoff; Junling Gao; Tiffany J Dunn; Luis Ojeda; Ping Wu
Journal:  Am J Stem Cells       Date:  2011-08-19

Review 5.  Beyond the rat models of human neurodegenerative disorders.

Authors:  Ondrej Bugos; Mangesh Bhide; Norbert Zilka
Journal:  Cell Mol Neurobiol       Date:  2009-03-05       Impact factor: 5.046

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.